Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) does about 25.10M shares in volume on a normal day but saw 4993257 shares change hands in Monday trading. The company now has a market cap of 116.77M USD and an enterprise value of about $71.93M. Its current market price is $0.89, marking a decrease of -7.66% compared to the previous close of $0.96. The 52 week high reached by this stock is $5.38 whilst the lowest price level in 52 weeks is $0.39. The script in recent trading has seen the stock touch a high of $0.9599 and a low of $0.87.

Tonix Pharmaceuticals Holding Corp. (TNXP) has a 20-day trading average at $1.0134 and the current price is -83.55% off the 52-week high compared with 126.86% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.9395 and its 200-day simple moving average is $0.9430. If we look at the stock’s price movements over the week, volatility stands at 11.07%, which decreases to 10.85% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 45.93 to suggest the stock is neutral.

1 analysts observing the Tonix Pharmaceuticals Holding Corp. (TNXP) stock have set the 12-month price targets for the company’s shares at between $3.00 and $3.00. The median price target is 70.33% away from the current levels at $3.00.

FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 18, 2019 when ROTH Capital upgraded the stock to “Buy” and issued a price target of $4. ROTH Capital also upgraded the stock to “Buy” from Neutral on August 18, 2017 at a price target of $6.

The current price level is -14.15%, -5.23%, and -7.00% away from its SMA20, SMA50, and SMA200 respectively, with the TNXP price moving above the 50-day SMA on August 31. Tonix Pharmaceuticals Holding Corp. (TNXP) stock is up 5.97% over the week and -31.38% over the past month. Its price is -24.34% year-to-date and -79.51% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.23 below consensus estimates by -$0.01. The company’s next earnings report is expected on 11/06/2020, with forecasts estimating quarterly EPS at -$0.16 and -$0.75 for whole year. TNXP’s earnings per share are forecast to grow by 96.10% this year and 36.00% over next year.

Its 12-month price target is $3.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $3.00.

Outstanding shares total 130.27M with insiders holding 0.05% of the shares and institutional holders owning 7.00% of the company’s common stock. The company has a return on equity of -162.10%. The beta has a value of 1.68. Price to book ratio is 1.03.

According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has added its position in Tonix Pharmaceuticals Holding Corp. (TNXP) to 444,164 shares, mirroring a recent increase by 15.94%. Vanguard Extended Market Index Fu added 61080.0 shares of Tonix Pharmaceuticals Holding Corp. common stock bringing its total worth to about $0.57 million at the end of recent close, SEC documents show. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.07% position in Tonix Pharmaceuticals Holding Corp. thanks to 83212.0 shares amounting to $0.11 million.